View the web version of this email  
  Jul 5, 2021 Visit website  

The Guangzhou Sino-Israel Biotech Investment Fund (GIBF) was launched in 2016 with financial backing from the Guangzhou government. The fund was established by luminaries including Dr Yehoshua (Shuki) Gleitman (former chief scientist of the State of Israel), Professor Shlomo Noy (former director general of Israel’s largest hospital, Sheba Medical Centre), Avner Lushi (who served in Israel’s prime minister’s office and is a veteran healthcare investor), and Carl Geng (formerly a senior official at the International Department of China’s Ministry of Foreign Affairs and a delegate to the UN). Its first investment vehicle was sized at $100 million and included 12 portfolio companies; GIBF is already raising its second fund with a target of $300 million.

WiC spoke to Lushi and Geng about how the unique partnership with the Guangzhou local government is managed, the fund’s vision, as well as China’s growing importance in multicentre research trials for innovative drugs. Click here to read the Q&A.

Steven Irvine
Editor, Week in China

  Unsubscribe        About Us        Forward to a friend        Preference Center  
  © 2021 Week in China is published weekly by ChinTell Limited, a company based in Hong Kong. All rights reserved.